|
Code
|
Description
|
Qty
|
Each
|
Total
|
 |
|
|
TT-MS-s |
Trial TRAX Multiple Sclerosis - Single User
Report: Trial TRAX-Multiple Sclerosis (October 2007)
Clinical Intelligence Monitoring Brief provides analysis of ongoing clinical studies for competitors within the Multiple Sclerosis therapeutic area. Single User. |
|
$1,000.00
|
$1,000.00
|
|
|
TCI-MS-g |
TCI Multiple Sclerosis - Global License
Report: Therapeutic Clinical Intelligence-Multiple Sclerosis (April 2007)
Detailed assessment of the clinical profiles of currently marketed drugs, and the orally formulated compounds & novel biologics in development for MS. Group license. |
|
$9,000.00
|
$9,000.00
|
|
|
TCI-T2D-s |
TCI Type 2 Diabetes Pipelline - Single User
Report: Therapeutic Clinical Intelligence-Type 2 Diabetes Pipeline (June 2008)
Report profiles the 35 most promising compounds in mid-to-late stage development for the treatment of Type-2 Diabetes. Single User |
|
$4,500.00
|
$4,500.00
|
|
|
TT-MS-g |
Trial TRAX Multiple Sclerosis - Group License
Report: Trial TRAX-Multiple Sclerosis (October 2007)
Clinical Intelligence Monitoring Brief provides analysis of ongoing clinical studies for competitors within the Multiple Sclerosis therapeutic area. Group License. |
|
$2,000.00
|
$2,000.00
|
|
|
TCI-P-g |
TCI Psoriasis - Group License
Report: Therapeutic Clinical Intelligence-Psoriasis (August 2007)
Report provides detailed information & analysis of the clinical data on key marketed & pipeline competitors in Psoriasis therapeutics market. Group license. |
|
$1,500.00
|
$1,500.00
|
|
|
TT-A-s |
Trial TRAX Alzheimer's - Single User
Report: Trial TRAX-Alzheimer's (September 2007)
Report provides detailed information & analysis of the clinical data on key marketed & pipeline competitors in Alzheimer therapeutics market. Single user. |
|
$700.00
|
$700.00
|
|
|
TCI-RA-s |
TCI Rheumatoid Arthritis - Single User
Report: Therapeutic Clinical Intelligence-Rheumatoid Arthritis (January 2009)
This report provides an exhaustive compilation and in-depth assessment of the entire clinical R&D competitive landscape for RA therapeutics. |
|
$2,300.00
|
$2,300.00
|
|
|
TCI-IBD-g |
TCI Inflammatory Bowel Disease - Global License
Report: Therapeutic Clinical Intelligence-Inflammatory Bowel Disease (March 2007)
Report provides detailed information & analysis of the clinical data on key marketed & pipeline competitors in IBD therapeutics market. Global license. |
|
$7,200.00
|
$7,200.00
|
|
|
TCI-IBD-s |
TCI Inflammatory Bowel Disease - Single User
Report: Therapeutic Clinical Intelligence-Inflammatory Bowel Disease (March 2007)
Report provides detailed information & analysis of the clinical data on key marketed & pipeline competitors in IBD therapeutics market. Single user. |
|
$3,100.00
|
$3,100.00
|
|
|
TCI-RA-g |
TCI Rheumatoid Arthritis - Group License
Report: Therapeutic Clinical Intelligence-Rheumatoid Arthritis (January 2009)
This report provides an exhaustive compilation and in-depth assessment of the entire clinical R&D competitive landscape for RA therapeutics. |
|
$2,500.00
|
$2,500.00
|
|
|
TCI-T2D-g |
TCI Type 2 Diabetes Pipelline - Group License
Report: Therapeutic Clinical Intelligence-Type 2 Diabetes Pipeline (June 2008)
Report profiles the 35 most promising compounds in mid-to-late stage development for the treatment of Type-2 Diabetes. Group license. |
|
$7,000.00
|
$7,000.00
|
|
|
TT-RA-s |
Trial TRAX Rheumatoid Arthritis- Single User
Report: Trial TRAX-Rheumatoid Arthritis (September 2007)
Clinical Intelligence Monitoring Brief provides analysis of ongoing clinical studies for competitors within the Multiple Sclerosis therapeutic area. Single User. |
|
$600.00
|
$600.00
|
|
|
TT-A-g |
Trial TRAX Alzheimer's - Group License
Report: Trial TRAX-Alzheimer's (September 2007)
Report provides detailed information & analysis of the clinical data on key marketed & pipeline competitors in Alzheimer therapeutics market. Group license. |
|
$1,200.00
|
$1,200.00
|
|
|
TCI-MS-s |
TCI Multiple Sclerosis - Single User
Report: Therapeutic Clinical Intelligence-Multiple Sclerosis (April 2007)
Detailed assessment of the clinical profiles of currently marketed drugs, and the orally formulated compounds & novel biologics in development for MS. Single User. |
|
$4,100.00
|
$4,100.00
|
|
|
Subtotal: |
$46,700.00 |
